PT3774862T - Novos análogos de glp-1 - Google Patents

Novos análogos de glp-1

Info

Publication number
PT3774862T
PT3774862T PT197249154T PT19724915T PT3774862T PT 3774862 T PT3774862 T PT 3774862T PT 197249154 T PT197249154 T PT 197249154T PT 19724915 T PT19724915 T PT 19724915T PT 3774862 T PT3774862 T PT 3774862T
Authority
PT
Portugal
Prior art keywords
analogues
novel glp
glp
novel
Prior art date
Application number
PT197249154T
Other languages
English (en)
Original Assignee
Sun Pharmaceutical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Ind Ltd filed Critical Sun Pharmaceutical Ind Ltd
Publication of PT3774862T publication Critical patent/PT3774862T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Transmission And Conversion Of Sensor Element Output (AREA)
PT197249154T 2018-04-05 2019-04-05 Novos análogos de glp-1 PT3774862T (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201821013109 2018-04-05
IN201821040468 2018-10-26
IN201821040474 2018-10-26

Publications (1)

Publication Number Publication Date
PT3774862T true PT3774862T (pt) 2022-09-05

Family

ID=66589592

Family Applications (2)

Application Number Title Priority Date Filing Date
PT197249154T PT3774862T (pt) 2018-04-05 2019-04-05 Novos análogos de glp-1
PT221774037T PT4122954T (pt) 2018-04-05 2019-04-05 Novos análogos de glp-1

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT221774037T PT4122954T (pt) 2018-04-05 2019-04-05 Novos análogos de glp-1

Country Status (30)

Country Link
US (6) US11447535B2 (pt)
EP (3) EP4122954B1 (pt)
JP (2) JP7250814B2 (pt)
KR (1) KR20200141469A (pt)
CN (2) CN112236444A (pt)
AU (2) AU2019247936C1 (pt)
BR (1) BR112020020419A2 (pt)
CA (1) CA3095988A1 (pt)
CL (1) CL2020002574A1 (pt)
CO (1) CO2020012425A2 (pt)
DK (2) DK3774862T3 (pt)
EC (1) ECSP20070185A (pt)
ES (2) ES2925678T3 (pt)
FI (1) FI4122954T3 (pt)
HR (2) HRP20221054T1 (pt)
HU (1) HUE060135T2 (pt)
IL (1) IL277483A (pt)
JO (1) JOP20200251A1 (pt)
LT (2) LT3774862T (pt)
MX (2) MX2020010505A (pt)
PE (1) PE20211417A1 (pt)
PH (1) PH12020551591A1 (pt)
PL (2) PL4122954T3 (pt)
PT (2) PT3774862T (pt)
RS (2) RS65639B1 (pt)
SG (1) SG11202009467YA (pt)
SI (2) SI4122954T1 (pt)
UA (1) UA128210C2 (pt)
WO (1) WO2019193576A1 (pt)
ZA (1) ZA202306729B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL4122954T3 (pl) * 2018-04-05 2024-08-12 Sun Pharmaceutical Industries Limited Nowe analogi GLP-1
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
TW202216746A (zh) * 2020-06-22 2022-05-01 印度商太陽製藥工業有限公司 長效型ｇｌｐ－１／ｇｉｐ雙重促效劑
PE20231309A1 (es) * 2020-10-17 2023-08-24 Sun Pharmaceutical Ind Ltd Agonistas duales glp-1/gip
CN114685646B (zh) * 2020-12-31 2023-04-07 厦门赛诺邦格生物科技股份有限公司 一种多肽侧链类似物的制备方法及其应用
JP2023554693A (ja) 2021-01-20 2023-12-28 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法
CN116514952B (zh) * 2022-10-13 2024-02-02 江苏师范大学 一类glp-1类似物及其应用
CN117756914B (zh) * 2023-12-15 2024-09-03 瀚晖制药有限公司 依柯胰岛素的制备方法

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849708B1 (en) 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
PT944648E (pt) 1996-08-30 2007-06-26 Novo Nordisk As Derivados do glp-1.
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
AU2610899A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally modified glp-1 derivatives
JP2002508162A (ja) 1998-02-27 2002-03-19 ノボ ノルディスク アクティーゼルスカブ Ｎ末端を短縮したｇｌｐ−１誘導体
JP2003522099A (ja) 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ 遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
DE69942306D1 (de) 1998-02-27 2010-06-10 Novo Nordisk As Abkömmlinge von glp-1 analogen
FR2777283B1 (fr) 1998-04-10 2000-11-24 Adir Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP2322545A1 (en) 1998-12-07 2011-05-18 Ipsen Pharma Analogues of GLP-1
PL206302B1 (pl) 2000-06-16 2010-07-30 Elli Lilly And Companyelli Lilly And Company Związek GLP-1
US7271149B2 (en) 2000-12-07 2007-09-18 Eli Lilly And Company GLP-1 fusion proteins
BR0306706A (pt) 2002-01-08 2007-03-27 Lilly Co Eli peptìdeo glp-1 estendido, métodos de estimulação do receptor de glp-1 em um indivìduo necessitando de normalização de glicose sanguìnea, de tratamento de um indivìduo profilaticamente para diabetes independente de insulina, de redução ou de manutenção do peso corporal, de tratamento da obesidade, e de tratamento de doenças, em um indivìduo necessitando do mesmo, uso de um composto de glp-1, processo de preparação de uma formulação farmacêutica, e, formulação farmacêutica
KR20050049525A (ko) 2002-10-11 2005-05-25 가부시키가이샤산와카가쿠켄큐쇼 Ｇｌｐ-1 유도체 및 그의 경점막 흡수형 제제
WO2004078777A2 (en) 2003-03-04 2004-09-16 Biorexis Pharmaceutical Corporation Dipeptidyl-peptidase protected proteins
ES2383752T3 (es) 2003-05-15 2012-06-26 Trustees Of Tufts College Analogos estables de GLP-1
BRPI0414539B8 (pt) 2003-09-19 2021-05-25 Novo Nordisk As composto, composição farmacêutica, e, uso de um composto
JP2007536214A (ja) 2003-12-16 2007-12-13 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス Ｇｌｐ−１類似体
EP1799710A2 (en) 2004-10-07 2007-06-27 Novo Nordisk A/S Protracted glp-1 compounds
MX2007011307A (es) 2005-03-18 2007-10-08 Novo Nordisk As Compuestos de glp-1 extendidos.
TWI372629B (en) * 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
WO2006121860A2 (en) 2005-05-06 2006-11-16 Bayer Pharmaceuticals Corporation Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use
JP2009507844A (ja) 2005-09-08 2009-02-26 トラスティーズ オブ タフツ カレッジ 安定化ｇｌｐ−１類似体
ES2336575T3 (es) 2005-09-22 2010-04-14 Biocompatibles Uk Limited Polipeptidos de fusion glp-1 (peptido-1 similar al glucagon) con resistencia aumentada a la peptidasa.
WO2009030771A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
CA2702289A1 (en) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Compounds exhibiting glucagon antagonist and glp-1 agonist activity
CN102791731B (zh) 2009-12-16 2016-04-20 诺沃—诺迪斯克有限公司 Glp-1类似物和衍生物
US8951959B2 (en) 2010-04-27 2015-02-10 Betta Pharmaceuticals Co., Ltd. Glucagon-like peptide-1 analogues and uses thereof
WO2012016419A1 (zh) 2010-08-06 2012-02-09 浙江贝达药业有限公司 Glp-1衍生物及其应用
ES2913803T3 (es) 2010-11-09 2022-06-06 Novo Nordisk As Derivados de GLP-1 diacilados
EP3225631B1 (en) 2011-04-12 2019-01-09 Novo Nordisk A/S Double-acylated glp-1 derivatives
WO2012150503A2 (en) 2011-05-03 2012-11-08 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
ES2626013T3 (es) 2011-09-06 2017-07-21 Novo Nordisk A/S Derivados de GLP-1
EP2578599A1 (en) 2011-10-07 2013-04-10 LanthioPep B.V. Cyclic analogs of GLP-1 and GLP-1 related peptides
EP2846823B1 (en) 2012-05-08 2019-12-04 Novo Nordisk A/S Double-acylated glp-1 derivatives
US11274135B2 (en) 2012-05-08 2022-03-15 Novo Nordisk A/S Double-acylated GLP-1 derivatives
MX2014015423A (es) 2012-06-14 2015-04-09 Sanofi Sa Analogos de peptido de exedina-4.
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
TWI617574B (zh) 2012-12-11 2018-03-11 梅迪繆思有限公司 用於治療肥胖之升糖素與ｇｌｐ－１共促效劑
PE20151239A1 (es) 2012-12-21 2015-09-08 Sanofi Sa Derivados de exendina-4 funcionalizada
EP3010546B1 (en) 2013-06-20 2017-08-09 Novo Nordisk A/S Glp-1 derivatives and uses thereof
WO2014209886A1 (en) 2013-06-23 2014-12-31 Wisconsin Alumni Research Foundation Alpha/beta-polypeptide analogs of glucagon-like peptid-1
JP6139712B2 (ja) 2013-07-04 2017-05-31 ノヴォ ノルディスク アー／エス Ｇｌｐ−１様ペプチドの誘導体及びその使用
EP3033112B1 (en) 2013-08-15 2020-10-07 Novo Nordisk A/S Glp-1 derivatives, and uses thereof
DK3057984T3 (en) * 2013-10-17 2018-10-08 Zealand Pharma As ACYLED GLUCAGON ANALOGS
WO2015086686A2 (en) 2013-12-13 2015-06-18 Medimmune Limited Protease resistant peptides
WO2015086731A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
ES2739289T3 (es) 2014-11-27 2020-01-30 Novo Nordisk As Derivados de GLP-1 y sus usos
CN107108714B (zh) 2014-12-17 2022-02-08 诺和诺德股份有限公司 Glp-1衍生物及其用途
TWI726889B (zh) 2015-06-10 2021-05-11 英商梅迪繆思有限公司 蛋白酶抗性之脂化肽
WO2017035432A1 (en) 2015-08-26 2017-03-02 Robert Doyle Coagonists of glucagon-like peptide 1 receptor and neuropeptide y2 receptor
WO2017149070A1 (en) 2016-03-03 2017-09-08 Novo Nordisk A/S Glp-1 derivatives and uses thereof
CA3025592A1 (en) 2016-06-09 2017-12-14 Medimmune Limited Protease-resistant mono-lipidated peptides
WO2018083335A1 (en) 2016-11-07 2018-05-11 Novo Nordisk A/S Dchbs-active esters of peg compounds and their use
TW201833131A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 作為胜肽類ｇｌｐ１／升糖素／ｇｉｐ受體促效劑之新化合物
WO2018178796A1 (en) * 2017-03-27 2018-10-04 Sun Pharmaceutical Industries Limited Method for making kex1 protease sensitive polypeptides using yeast strain
CA3093221A1 (en) 2018-03-09 2019-09-12 Enzypep B.V. Chemo-enzymatic synthesis of liraglutide, semaglutide and glp-1
PL4122954T3 (pl) * 2018-04-05 2024-08-12 Sun Pharmaceutical Industries Limited Nowe analogi GLP-1

Also Published As

Publication number Publication date
EP4122954B1 (en) 2024-04-03
ECSP20070185A (es) 2021-01-29
US11447535B2 (en) 2022-09-20
BR112020020419A2 (pt) 2021-01-19
DK3774862T3 (da) 2022-09-05
DK4122954T3 (da) 2024-06-10
CA3095988A1 (en) 2019-10-10
AU2019247936B2 (en) 2023-03-02
FI4122954T3 (fi) 2024-06-18
US20220402991A1 (en) 2022-12-22
EP3774862B1 (en) 2022-06-08
PL4122954T3 (pl) 2024-08-12
HRP20240749T1 (hr) 2024-09-13
PL3774862T3 (pl) 2022-10-03
HRP20221054T1 (hr) 2022-11-11
US11873328B2 (en) 2024-01-16
LT3774862T (lt) 2022-09-12
CN117964735A (zh) 2024-05-03
UA128210C2 (uk) 2024-05-08
RS63523B1 (sr) 2022-09-30
US20220402992A1 (en) 2022-12-22
EP4364751A2 (en) 2024-05-08
JOP20200251A1 (ar) 2020-10-04
EP3774862A1 (en) 2021-02-17
WO2019193576A1 (en) 2019-10-10
ES2925678T3 (es) 2022-10-19
US20190309040A1 (en) 2019-10-10
PE20211417A1 (es) 2021-08-02
JP7250814B2 (ja) 2023-04-03
AU2019247936A1 (en) 2020-10-15
LT4122954T (lt) 2024-06-25
ZA202306729B (en) 2024-03-27
CO2020012425A2 (es) 2020-12-21
ES2980707T3 (es) 2024-10-02
PH12020551591A1 (en) 2021-08-16
US20240199718A1 (en) 2024-06-20
EP4122954A1 (en) 2023-01-25
SG11202009467YA (en) 2020-10-29
AU2019247936C1 (en) 2023-06-15
US11485766B2 (en) 2022-11-01
EP4364751A3 (en) 2024-06-26
SI4122954T1 (sl) 2024-07-31
SI3774862T1 (sl) 2022-10-28
CN112236444A (zh) 2021-01-15
IL277483A (en) 2020-11-30
JP2021520346A (ja) 2021-08-19
MX2024007688A (es) 2024-07-09
PT4122954T (pt) 2024-06-05
US20200362007A1 (en) 2020-11-19
CL2020002574A1 (es) 2021-06-04
JP2023078367A (ja) 2023-06-06
AU2023203430A1 (en) 2023-06-29
HUE060135T2 (hu) 2023-02-28
US11866477B2 (en) 2024-01-09
RS65639B1 (sr) 2024-07-31
US20210206823A1 (en) 2021-07-08
US11242373B2 (en) 2022-02-08
MX2020010505A (es) 2021-01-15
KR20200141469A (ko) 2020-12-18

Similar Documents

Publication Publication Date Title
IL277483A (en) New anti-GLP-1 analogs
CA190078S (en) Case
GB202005105D0 (en) n
IL283385A (en) Different analogs of gip peptide
GB2582783B (en) Checkpointing
GB2577682B (en) Auto-injector
PL3630806T3 (pl) Analogi peptydów gip o długotrwałym działaniu
GB2589548B (en) Auto-Injector
GB2575149B (en) Lanyards
GB201800400D0 (en) Structural components
EP3906225C0 (en) PANTOTHENAMIDE ANALOGUES
ZA202100322B (en) Polytunnel structure
GB2591977B (en) Auto-Injector
GB202002530D0 (en) N
CA204449S (en) Auto-injector
CA189432S (en) Case
CA189431S (en) Case
GB2576916B (en) Polytunnel structure
GB202006585D0 (en) n
GB2575634B (en) Polytunnel structure
GB201908550D0 (en) n
GB201818676D0 (en) Polytunnel structure
GB201803158D0 (en) Improved structure